PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 38/17, 39/395, A61P 15/00 — A1

(11) International Publication Number: WO 00/43031

(43) International Publication Date: 27 July 2000 (27.07.00)

(21) International Application Number: PCT/IB00/00052

(22) International Filing Date: 19 January 2000 (19.01.00)

(30) Priority Data:
99101194.1 22 January 1999 (22.01.99) EP

(71) Applicant *(for all designated States except US)*: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; 15, Pieterrmmai, Curacao (AN).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BORRELLI, Francesco [IT/IT]; Via Raffaele De Cesare, 119, I-00179 Roma (IT). D'ANTONIO, Mauro [IT/IT]; Via Rossini Palazzo Conte, Parco Cerasole, I-81100 Caserta (IT). MARTELLI, Fabrizio [IT/IT]; Via Sambruccio D'Alando, 14, I-00162 Roma (IT).

(74) Agents: MOINAS, Michel et al.; Moinas Savoye & Cronin, 42, rue Plantamour, Ch-1201 Genève (CH).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TUMOR NECROSIS FACTOR ANTAGONISTS AND THEIR USE IN ENDOMETRIOSIS

(57) Abstract

Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected among various classes of molecules but preferably are soluble TNF receptors. The antagonists are useful for the regression of endometriotic lesions and, if combined with other active ingredients, for amelioration of related disorders, like infertility.